Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 8/20 | 0.62 |
| ▸ | AURKA | O14965 | 10/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760630 | 0.95 | ACVR1 (0.61) | ACVR1AURKAAURKBABL1BCR | |
| SCHEMBL4764362 | 0.94 | ACVR1 (0.55) | ACVR1AURKAAURKBABL1BCR | |
| SCHEMBL4629173 | 0.93 | ABL1 (0.57) | ACVR1AURKAAURKBABL1BCR | |
| SCHEMBL5094702 | 0.92 | ABL1 (0.56) | ACVR1AURKAAURKBABL1BCR | |
| SCHEMBL4792973 | 0.91 | ACVR1 (0.60) | ACVR1AURKAAURKBABL1BCR | |
| SCHEMBL5096947 | 0.91 | ACVR1 (0.62) | ACVR1AURKAAURKBABL1BCR | |
| SCHEMBL4629187 | 0.91 | ACVR1 (0.62) | ACVR1AURKAAURKBABL1BCR | |
| SCHEMBL5094718 | 0.90 | ACVR1 (0.62) | ACVR1AURKAAURKBABL1BCR | |
| SCHEMBL5103247 | 0.87 | ACVR1 (0.69) | ACVR1ABL1BCRJAK2JAK3 | |
| SCHEMBL5094740 | 0.87 | ACVR1 (0.53) | ACVR1AURKAAURKBABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | SMITHKLINE BEECHAM CORPORATION | 2008-10-02 | — | — | US | claimed |
| EP-1917258-A2 | PYRIMIDINYL-PYRAZOLE INHIBITORS OF AURORA KINASES | SmithKline Beecham Corporation (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2007024843-A2 | PYRIMIDINYL-PYRAZOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-01 | — | — | WO | claimed |
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | SMITHKLINE BEECHAM CORPORATION | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | AURKA, AURKC, PLK1 | ACVR1 1609/4885AURKA 1/4885AURKB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.